favorable opinion of the FDA on anti-Covid treatment

(CercleFinance.com) – Merck announced last night that the US health authorities had issued a favorable opinion on its urgent registration request concerning molnupiravir, its treatment against Covid that it developed in collaboration with Ridgeback.

The FDA concluded by 13 to 10 that the benefits of the treatment outweighed the associated risks.

This advice is a first step before a final decision is made, knowing that the FDA generally has the habit of following the advice communicated by its advisory committees.

The announcement comes as Merck unveiled clinical results that were less encouraging than expected last week.

Among the 1,433 participants who joined the testing phase, molnupiravir reduced the risk of hospitalization or death to 6.8%, compared with 9.7% for placebo, i.e. a reduction of around 30%. .

This is worse than the rate of 50% which was first mentioned by the American laboratory.

Molnupiravir, an oral antiviral drug, is currently being considered for the treatment of mild or moderate forms of Covid-19.

Did you like this article ? Share it with your friends with the buttons below.